Search - tctmd.com

Displaying 1 - 20 of 117

Sort: Relevancy | Date

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

News Conference News ESC 2025

WHF Stresses the Importance of Polypills in Global Fight Against CVD

Yael L. Maxwell

September 09, 2025

News Conference News ESC 2025

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

Caitlin E. Cox

August 31, 2025

Presentation ESC 2025

Essence-TIMI 73b: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk

Presenter: Brian Bergmark

August 30, 2025

News Daily News

Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC

Yael L. Maxwell

August 18, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Daily News

Topline Data Point to Promise for VERVE-102 Gene-Editing Therapy

Caitlin E. Cox

April 14, 2025

Genetic Risk Score for Endothelial Cell Dysfunction Identifies Patients at Risk

News Daily News

Genetic Risk Score for Endothelial Cell Dysfunction May Help Hone ASCVD Care

Michael O'Riordan

February 27, 2025

News Conference News AHA 2024

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Michael O'Riordan

November 21, 2024

News Conference News ESC 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Michael O'Riordan

September 01, 2024

News Conference News ESC 2024

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

Caitlin E. Cox

August 31, 2024

News Daily News

ApoB Can Be High, Risky for ASCVD Even When LDL’s Normal

Yael L. Maxwell

June 17, 2024

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

News Conference News EACTS 2023

SWEDEHEART Hints at Mortality Benefit With Statins After SAVR

Michael O'Riordan

October 05, 2023

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

News Conference News ESC 2023

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

Michael O'Riordan

September 01, 2023

News Daily News

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Michael O'Riordan

July 20, 2023

News Daily News

Two New Studies Highlight Lack of Diversity in Cardiovascular RCTs

Michael O'Riordan

July 11, 2023

News Daily News

LDL Control Remains Poor in CAD Patients: NHANES

Michael O'Riordan

July 05, 2023

News Conference News EAS 2023

With New LDL Goalposts in FH, Combo Therapy Must Start Early

Michael O'Riordan

May 29, 2023

Advertisement

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

WHF Stresses the Importance of Polypills in Global Fight Against CVD

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

Essence-TIMI 73b: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk

Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Topline Data Point to Promise for VERVE-102 Gene-Editing Therapy

Genetic Risk Score for Endothelial Cell Dysfunction May Help Hone ASCVD Care

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

ApoB Can Be High, Risky for ASCVD Even When LDL’s Normal

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

SWEDEHEART Hints at Mortality Benefit With Statins After SAVR

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Two New Studies Highlight Lack of Diversity in Cardiovascular RCTs

LDL Control Remains Poor in CAD Patients: NHANES

With New LDL Goalposts in FH, Combo Therapy Must Start Early

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content